

Health industries strategic council: Sanofi doubles its participation in two funds dedicated to innovation

- * Sanofi Ventures increased to 330 million dollars and will open European office in Paris
- * Subscription of 50 million euros in the InnoBio 2 fund
- * Participation in the government's Health Data Hub initiative

Paris - July 10, 2018 - As part of the health industries strategic council (CSIS), meeting today in Paris under the auspices of the Prime Minister, Sanofi reinforced its commitment to innovation, doubling its participation in two investment funds dedicated to the life sciences.

On the one hand, the company increases the investment capacity of Sanofi Ventures, its venture capital fund, to \$330 million (€281 million). This entity also sees its scope extended to digital health. On the other hand, Sanofi has signed a memorandum of understanding with Bpifrance to launch InnoBio 2. By providing € 50 million to this fund, which will invest particularly in the digital sector, the company supports the development of innovative companies in the field of health, in France and Europe.

"With these strategic commitments, Sanofi is proud to contribute to the attractiveness of the health sector in France and internationally. In addition, each of the funds sees its skills extended to digital, essential to the performance of the pharmaceutical industry," said Olivier Brandicourt, Chief Executive Officer of Sanofi. "We are more than ever determined to consolidate the French ecosystem that exists in the life sciences to the benefit of patients."

Launched in 2012 in Cambridge, Massachusetts, Sanofi Ventures has completed 24 new investments, 12 initial public offerings and 1 trade sale, and 4 companies in its portfolio were the subject of strategic collaboration agreements with Sanofi. The fund is now extending its reach beyond the United States with the opening of a European office, based in Paris, and an office in Shanghai. The fund invests in the early stages of companies with promising product candidates that could enrich the Sanofi pipeline.

As for InnoBio 2, managed by Bpifrance (which will provide 49% of the fund), it ultimately aims for a size of between 200 and 250 million euros. InnoBio 2 will invest in biopharmaceutical products, bioprocess development, digital health with a strong link to prescription drugs, diagnostics and medical devices. Its duration is 10 years, extendable twice, for one year.

Sanofi will also participate in the government-initiated Health Data Hub, by opening up its DARWIN platform, which was launched last year. This platform compiles anonymous data from 300 million patients in 318 diseases and 45 studies. The goal is to improve the understanding, diagnosis, prevention, and treatment of diseases. Focusing on openness and sharing, Sanofi aims to provide all French, European and international academic and institutional organizations with its expertise in innovative analytical tools, using artificial intelligence as well as predictive or decision-making models.

Finally, in the digital health field, Sanofi plans to engage with start-ups in favor of digital in clinical research. Sanofi's, whose European digital clinical research team is based in Paris, will engage with French start-ups to develop digital services in clinical research, be it to include patients or to accompany them.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Media Relations Contact

Laurence Bollack
T: +33 (0)1 53 77 46 46
mr@sanofi.com

Investor Relations Contact

George Grofik
T: +33 (0)1 53 77 45 45
ir@sanofi.com

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the clinical development of and potential marketing approvals for the product. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "would be" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development of the product, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve the product or biological application that may be filed for the product as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of the product, the absence of guarantee that the product if approved will be commercially successful, risks associated with intellectual property, future litigation, the future approval and commercial success of therapeutic alternatives, and volatile economic conditions, as well as those risks discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2017. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.